TC Biopharm (Holdings) Plc (TCBP)
| Market Cap | 109.86K |
| Revenue (ttm) | 3.61M |
| Net Income (ttm) | -1.96M |
| Shares Out | 34.66K |
| EPS (ttm) | -68.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 766,154 |
| Open | 3.15 |
| Previous Close | 2.90 |
| Day's Range | 2.81 - 4.15 |
| 52-Week Range | 2.03 - 1,922.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 1,400.00 (+44,064.04%) |
| Earnings Date | Jan 9, 2024 |
About TCBP
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. [Read more]
Financial Performance
In 2022, TCBP's revenue was 3.84 million, an increase of 94.30% compared to the previous year's 1.98 million. Losses were -1.39 million, -89.76% less than in 2021.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to one analyst, the rating for TCBP stock is "Strong Buy" and the 12-month stock price forecast is $1,400.0.
News
TC BioPharm Announces Closing of $3.5 Million Public Offering
EDINBURGH, Scotland , Dec. 22, 2023 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic ga...
TC BioPharm Announces Pricing of $3.5 Million Public Offering
EDINBURGH, Scotland , Dec. 19, 2023 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic ga...
TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D
EDINBURGH, Scotland , Dec. 18, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TC BioPharm Announces Plan to Implement ADS Ratio Change
EDINBURGH, Scotland , Dec. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia
EDINBURGH, Scotland , Nov. 27, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results
No Significant Safety Concerns Observed in Safety Cohort Management expects to expand ACHIEVE trial in Q1 EDINBURGH, Scotland , Nov. 14, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" ...
TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials
Creates economic leverage with vertical integration of database and management EDINBURGH, Scotland , Nov. 2, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: T...
TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements
Excellos to provide scale up solution for final manufacturing in TCBP facility EDINBURGH, Scotland , Oct. 25, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: ...
TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AML
Filing is supported by strong clinical data and IND enabling pre-clinical data associated withTCB-008 in treatment of Acute Myeloid Leukemia EDINBURGH, Scotland , Oct. 23, 2023 /PRNewswire/ -- TC BioP...
TC BioPharm to Present at the LD Micro Main Event XVI
EDINBURGH, Scotland , Sept. 27, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic ga...
TC BioPharm Announces Grant Funding in Collaboration with Queen Mary University of London (QMUL)
EDINBURGH, Scotland , Sept. 5, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic ga...
TC BioPharm to Present at H.C. Wainwright 25th Annual Global Investment Conference
EDINBURGH, Scotland , Aug. 29, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TC BioPharm Maintains Nasdaq Listing
Regains Compliance with Rule 5550(b)(2) EDINBURGH, Scotland , July 31, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology co...
TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - July 6, 2023) - The Stock Day Podcast welcomed TC BioPharm Holdings, PLC. (NASDAQ: TCBP) ("the Company"), a clinical-stage biopharmaceutical company focused on the ...
TC BioPharm to Present at LD Micro Invitational XIII Conference on June 7, 2023
EDINBURGH, Scotland , May 24, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamm...
TC BioPharm Increases Allogeneic Car and Partnering Focus for Advancement of TCB-008
Company highlights 2023 plan as it progresses towards IND submittal and Ovarian Cancer Treatments EDINBURGH, Scotland , April 26, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the ...
TC BioPharm to Present at the Sequire Investor Summit in Puerto Rico
EDINBURGH, Scotland, April 19, 2023 (GLOBE NEWSWIRE) -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic...
TC BioPharm Announces Closing of $5.5 Million Public Offering
EDINBURGH, Scotland , March 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic ga...
TC BioPharm Announces Pricing of $5.5 Million Public Offering
EDINBURGH, Scotland , March 28, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic ga...
TC Biopharm Announces Corporate Restructuring, Reduction in Overhead
Extends cash runway Realigned to reflect corporate strategic vision EDINBURGH, Scotland , March 22, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a cl...
TC BioPharm Receives Extension from Nasdaq Hearings Panel to Regain Compliance With Listing Rule 5550(b)(2)
EDINBURGH, Scotland , March 16, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic g...
TC BioPharm Shifts Focus to FDA Clinical Trials
Company to explore US IND pathway for additional combination trials EDINBURGH, Scotland , March 7, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a cli...
TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer
EDINBURGH, Scotland , Feb. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T cell Therapies
EDINBURGH, Scotland , Feb. 21, 2023 /PRNewswire/ -- TC BioPharm(Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...
TC BioPharm Announces New Chair of the Board, Arlene Morris
EDINBURGH, Scotland , Feb. 14, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfo...